Autoimmune encephalitis: Should we consider third-line immunotherapies earlier?

Eur J Neurol. 2023 May;30(5):1167-1169. doi: 10.1111/ene.15728. Epub 2023 Feb 20.

Authors

Mark J Kelly^{1

2}, Sarosh R Irani^{1

3}

Affiliations

¹ Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
² Royal College of Surgeons in Ireland, Dublin, Ireland.
³ Department of Neurology, John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK.

PMID: 36794337
DOI: 10.1111/ene.15728

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Autoantibodies
Autoimmune Diseases of the Nervous System* / therapy
Encephalitis* / therapy
Hashimoto Disease* / drug therapy
Humans
Immunotherapy

Substances

Autoantibodies

Supplementary concepts

Hashimoto's encephalitis

Grants and funding